Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006456|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : February 24, 2010
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific||Radiation: stereotactic radiosurgery||Phase 2|
- Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.
- Assess the toxicities of this treatment regimen in these patients.
- Determine tumor response and cause of death in these patients treated with this regimen.
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Masking:||None (Open Label)|
|Official Title:||Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors|
|Study Start Date :||February 1999|
|Primary Completion Date :||November 2004|
|Study Completion Date :||November 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006456
|United States, Virginia|
|Massey Cancer Center|
|Richmond, Virginia, United States, 23298-0058|
|Study Chair:||Danny Y. Song, MD||Massey Cancer Center|